India’s Bharat Biotech will be producing part of the world’s only malaria vaccine that has been developed by Pharma major GSK, and was recently approved by WHO (World Health Organisation). However, it may take a couple of years before the vaccine is launched in the market for use. In January, this year, Hyderabad-based vaccine major announced that it entered a product transfer partnership with the pharma major GSK for its malaria vaccine, RTS, S/AS01E1.As part of this partnership, GSK would transfer RTS manufacturing technology to Bharat Biotech to produce the S antigen component of the malaria vaccine, and the license on all rights pertaining to it. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to Bharat Biotech.
Related Articles

Business & Economics
GeM closes in on Amazon, Flipkart in gross merchandise value

Business & Economics
Oil at 6-month low, petrol at breakeven
International oil prices have hit a six-month low, helping Indian fuel retailers breakeven on petrol but they continue to lose money on diesel – the most used fuel in the country, officials said. The world’s […]

Be the first to comment